bioMérieux

Strategic area of application
In Vitro diagnostic

Application market
Infectiology - Parasitology - Others

Activities
Diagnostics

Technologies
Analytical & Diagnostic services - (Bio) Informatics & software - Molecular Biology and Nucleic acid

Presentation of company's activity
Pioneering Diagnostics A world leader in the field of in vitro diagnostics for more than 50 years, bioMérieux is present in more than 150 countries through 42 subsidiaries and a large network of distributors. In 2016, revenues reached €2,103 million, with more than 90% of international sales. bioMérieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products. bioMérieux is listed on the Euronext Paris market (Symbol: BIM – ISIN: FR0010096479). Corporate website: www.biomerieux.com / www.biofiredx.com Investor website: www.biomerieux-finance.com

Key features of company
• € 2.103 billion in sales (as of Dec. 31, 2016) • 2 main applications: o Clinical Diagnostics: ~ 80% of sales, o Industrial Microbiology: ~ 18% of sales. • 9,800 employees (full-time equivalents) at the end of December 2016. • Present in more than 150 countries through 42 subsidiaries, o 90% of sales outside France. • 18 production sites (nearly 3,000 employees) • 20 R&D sites (1,600 employees) • bioMérieux is listed on NYSE Euronext Paris.

Recent news
bioMérieux’s latest news on:www.biomerieux.com

Higlights

Our Assets: • A strong commitment and a long-term vision (family-owned company). • World leader in clinical microbiology. • Leader in industrial microbiological control for the agri-food, cosmetics and pharmaceutical industries. • Leader in the syndromic molecular diagnosis of infectious diseases. • A broad international footprint. • Installed base of some 86,900 instruments worldwide (as of December 31, 2016).

Presentation of company's technologies

bioMérieux is one of the few companies mastering the complete range of technologies essential for in vitro diagnostics:

We have a long and successful tradition of integrating the 3 detection technologies into fully automated systems, comprised of instruments, software and reagents. Systems are constantly evolving and must integrate an increasing number of parameters.